Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer

被引:151
作者
Javle, M. M.
Gibbs, J. F.
Iwata, K. K.
Pak, Y.
Rutledge, P.
Yu, J.
Black, J. D.
Tan, D.
Khoury, T.
机构
[1] Univ Texas Houston, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
[2] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
关键词
pancreatic neoplasms; cell transformation-neoplastic; mitogen-activated protein kinases;
D O I
10.1245/s10434-007-9540-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: EMT or transformation to the mesenchymal phenotype plays an important role in tumor invasion and metastasis. In vitro data suggest that mesenchymal transformation may correlate with the activation of PI3 kinase and Ras/Erk pathways. We investigated the expression of EMT markers (low E-cadherin, high fibronectin, and vimentin) and their association with p-Erk in resected pancreatic cancer. Methods: Clinical data/surgical specimens from 34 consecutive pancreatic cancer patients (pts) who underwent pancreatectomy were included. Immunohistochemical staining was performed on formalin-fixed paraffin-embedded tissues using monoclonal antibodies against vimentin, fibronectin, E-cadherin, and p-Erk. The results were correlated with clinicopathological parameters and survival. Survival analysis (log-rank test, Cox proportional hazard model), categorical data analysis (Pearson's chi-square, Fisher's exact test) and Kendall's tau were performed at a significance level of 0.05. Results: The patient population was formed from 13 males and 21 females, with a median age of 66 years (range 38-84 years); American Joint Committee on Cancer (AJCC) stage 1 (n = 2), 2 (n = 27), 3 (n = 5); histological grade 1 (n = 4), 2 (n = 13), 3 (n = 16), 4 (n = 1). Median survival was 15 months (95% CI: 11-24 months). Fibronectin overexpression correlated with the presence of vimentin (p = 0.0048) and activated Erk (p = 0.0264). There was a borderline association of fibronectin with worsening grade (p = 0.06). A negative association between vimentin and E-cadherin was noted (p = 0.0024). Increased fibronectin or vimentin and decreased E-cadherin correlated with poor survival. Conclusion: EMT is associated with poor survival in surgically resected pancreatic adenocarcinoma. A correlation between activated Erk and fibronectin was identified that may open avenues for targeted therapy for this subgroup.
引用
收藏
页码:3527 / 3533
页数:7
相关论文
共 31 条
  • [1] Epithelial mesenchymal interactions in cancer and development
    Arias, AM
    [J]. CELL, 2001, 105 (04) : 425 - 431
  • [2] Colorectal cancer progression -: Integrin αvβ6 and the epithelial-mesenchymal transition (EMT)
    Bates, RC
    [J]. CELL CYCLE, 2005, 4 (10) : 1350 - 1352
  • [3] Bates RC, 2005, CANCER BIOL THER, V4, P365
  • [4] Birchmeier C, 1996, ACTA ANAT, V156, P217
  • [5] cAMP protection of pancreatic cancer cells against apoptosis induced by ERK inhibition
    Boucher, MJ
    Duchesne, C
    Lainé, J
    Morisset, J
    Rivard, N
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 285 (02) : 207 - 216
  • [6] Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma
    Chadha, Krishdeep S.
    Khoury, Thaer
    Yu, Jihnhee
    Black, Jennifer D.
    Gibbs, John F.
    Kuvshinoff, Boris W.
    Tan, Dongfeng
    Brattain, Michael G.
    Javle, Milind M.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (07) : 933 - 939
  • [7] Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: Role of fibroblast growth factor receptor-2
    Chaffer, Christine L.
    Brennan, Janelle P.
    Slavin, John L.
    Blick, Tony
    Thompson, Erik W.
    Williams, Elizabeth D.
    [J]. CANCER RESEARCH, 2006, 66 (23) : 11271 - 11278
  • [8] Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel
    Cheng, George Z.
    Chan, Joseph
    Wang, Qi
    Zhang, Weizhou
    Sun, Calvin D.
    Wang, Lu-Hai
    [J]. CANCER RESEARCH, 2007, 67 (05) : 1979 - 1987
  • [9] Should adjuvant therapy remain the standard of care for patients with resected adenocarcinoma of the pancreas?
    Chu, QYD
    Khushalani, N
    Javle, MM
    Douglass, HO
    Gibbs, JF
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2003, 10 (05) : 539 - 545
  • [10] Ellenrieder V, 2001, CANCER RES, V61, P4222